CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $198.59M, lower than 95% of all stocks globally
- PositionOperating margin is -49180%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
281.33BKRW198.59M · vs all stocks (USD)
Revenue (TTM)
59.44MKRW41.96K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-51.49%vs all stocks
Market Capitalization
281.33BKRW198.59M · vs all stocks (USD)
Enterprise Value
204.66BKRW144.47M · vs all stocks (USD)
Price to Book (MRQ)
10.67xvs Biotechnology peers
Enterprise to Revenue
3.44Kxvs Biotechnology peers
Enterprise to EBITDA
-7.21xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-82.55%vs Biotechnology peers
Return on Equity (TTM)
-134.20%vs Biotechnology peers
Revenue (TTM)
59.44MKRW41.96K · vs all stocks (USD)
Revenue per Share (TTM)
0.8150KRWUpdated Jul 15, 2026Gross Profit (TTM)
45.62MKRW32.20K · vs all stocks (USD)
EBITDA (TTM)
-28.38BKRW-20.04M · vs all stocks (USD)
Net Income (TTM)
-28.54BKRW-20.15M · vs all stocks (USD)
Operating Cash Flow (TTM)
-26.30BKRW-18.56M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.36BKRW-19.32M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
111.21MKRWFY2025 · Dec 31, 2025Gross Profit
111.21MKRWFY2025 · Dec 31, 2025Operating Income
-28.01BKRW-19.77M · vs all stocks (USD)
Pre-tax Income
-27.36BKRWFY2025 · Dec 31, 2025Net Income
-27.36BKRWFY2025 · Dec 31, 2025EBIT
-27.36BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.45BKRWFY2025 · Dec 31, 2025Research & Development
19.82BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
4.19BKRWFY2025 · Dec 31, 2025Other Operating Expenses
52.37MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
706.03MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
5.12MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-27.36BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-19.74BKRWFY2025 · Dec 31, 2025Free Cash Flow
-20.07BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
8.24BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-27.36BKRWFY2025 · Dec 31, 2025Stock-based Compensation
409.46MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-700.91MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
8.04BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-134.38MKRWFY2025 · Dec 31, 2025Capital Expenditures
-329.97MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-137.74MKRWFY2025 · Dec 31, 2025Purchase of Investments
-32.80BKRWFY2025 · Dec 31, 2025Sale of Investments
20.70BKRWFY2025 · Dec 31, 2025Other Investing Activity
-545.95MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.98BKRWFY2025 · Dec 31, 2025Other Financing Charges
-69.10MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
35.95BKRWFY2025 · Dec 31, 2025Shares Outstanding
80.06MSharesUpdated Jul 15, 2026Float Shares
28.20MSharesUpdated Jul 15, 2026% Held by Insiders
53.85%vs all stocks
% Held by Institutions
0.89%vs all stocks
Total Cash (MRQ)
18.99BKRW13.41M · vs all stocks (USD)
Total Cash per Share (MRQ)
255.69KRWUpdated Jul 15, 2026Total Debt (MRQ)
55.70MKRW39.32K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0024xvs Biotechnology peers
Current Ratio (MRQ)
5.39xvs Biotechnology peers
Book Value per Share (MRQ)
289.03KRWUpdated Jul 15, 2026Total Assets
33.15BKRW23.40M · vs all stocks (USD)
Total Current Assets
26.51BKRWFY2025 · Dec 31, 2025Total Liabilities
4.73BKRWFY2025 · Dec 31, 2025Total Non-current Assets
6.64BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
470.88MKRWFY2025 · Dec 31, 2025Total Current Liabilities
4.26BKRWFY2025 · Dec 31, 2025Cash Equivalents
8.24BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
8.24BKRWFY2025 · Dec 31, 2025Other Short-term Investments
15.20BKRWFY2025 · Dec 31, 2025Short-term Debt
54.98MKRWFY2025 · Dec 31, 2025Other Current Liabilities
20.00KRWFY2025 · Dec 31, 2025Long-term Debt
14.55MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
20.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
37.08BKRWFY2025 · Dec 31, 2025Retained Earnings
-138.09BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
28.42BKRW20.06M · vs all stocks (USD)
52-Week Low
2.78KKRWUpdated Jul 15, 202652-Week High
16.11KKRWUpdated Jul 15, 202652-Week Change
-51.49%vs all stocks
50-Day MA
4.84KKRWUpdated Jul 15, 2026200-Day MA
7.82KKRWUpdated Jul 15, 2026Avg 10-Day Volume
295.89KSharesUpdated Jul 15, 2026Avg 30-Day Volume
543.23KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-362.25KRWUpdated Jul 15, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -49180%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -491.8Industry median: -0.34Industry P5: -43.55Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
High structural barrier to entryNotable
Barrier to Entry: 1,025.802
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $198.59M, lower than 95% of all stocks globallySignificant
Market cap (USD): 198,593,373.744Global P5: 269,387,740.27
Revenue is $41,962, lower than 95% of all stocks globallySignificant
Revenue (USD): 41,962.014Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated